109.55 +0.15 (0.14%)
After hours: 7:19PM EST
|Bid||109.05 x 1300|
|Ask||111.00 x 800|
|Day's Range||108.15 - 114.49|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.
This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.
Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $133.24, marking a -0.61% move from the previous day.
In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $129.65, marking a +1.73% move from the previous day.
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $118.11, moving -0.85% from the previous trading session.
CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
Justin Gover became the CEO of GW Pharmaceuticals plc (NASDAQ:GWPH) in 1999. This report will, first, examine the CEO...
Thirteen analysts are covering GW Pharmaceuticals in October. Nine covered the stock in October 2018. The consensus target price for the stock is $226.85.